Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245230 · ClinicalTrials.gov registry record · Phase 1
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02245230 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 24 participants.
The verdict
NCT02245230, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to better understand the cardiovascular effects of the vasodilatory peptide Angiotensin (1-7) in human hypertension. In this study, the investigators will test the hypothesis that systemic Angiotensin (1-7) infusion produces negligible effects with intact baroreceptors, and that the cardiovascular effects of this peptide are unmasked following elimination of baroreflex buffering.
Interventions
- DRUG Angiotensin (1-7)
- DRUG Phenylephrine
- DRUG Trimethaphan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-01 |
| Est. Completion | 2023-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02245230
The ClinicalTrials.gov registry entry for NCT02245230 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Angiotensin (1-7) is the first listed.
NCT02245230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02245230 about?
NCT02245230 is a clinical study titled "Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension". The purpose of this study is to better understand the cardiovascular effects of the vasodilatory peptide Angiotensin (1-7) in human hypertension. In this study, the investigators will test the hypothesis that systemic Angiotensin (1-7) infusion produces negligible effects with intact baroreceptors, ...
What is the current status of trial NCT02245230?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-01. Estimated completion is 2023-12.
What interventions are being tested in trial NCT02245230?
The interventions under investigation include: Angiotensin (1-7) (DRUG), Phenylephrine (DRUG), Trimethaphan (DRUG).
Who is sponsoring clinical trial NCT02245230?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.